Nova Biomedical Corporation
Nova Biomedical Corporation, headquartered in the United States, is a leading innovator in the medical device industry, specialising in advanced diagnostic and monitoring solutions. Founded in 1976, the company has established a strong presence in key operational regions, including North America, Europe, and Asia. Renowned for its cutting-edge blood glucose monitoring systems and point-of-care testing devices, Nova Biomedical stands out for its commitment to accuracy and user-friendly design. The company’s flagship products, such as the Nova StatStrip® and the Nova Glucose Monitoring System, are widely recognised for their reliability and efficiency in clinical settings. With a robust market position, Nova Biomedical has achieved significant milestones, including numerous patents and awards for innovation. The company continues to lead the way in providing high-quality, cost-effective solutions that enhance patient care and streamline healthcare processes.
DitchCarbon Score
How does Nova Biomedical Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Nova Biomedical Corporation's score of 23 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Nova Biomedical Corporation's reported carbon emissions
Nova Biomedical Corporation, headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. As a result, Nova Biomedical's climate commitments and initiatives remain unclear, and there is no information available regarding their strategies for reducing carbon emissions or their alignment with industry standards such as the Science Based Targets initiative (SBTi). In the context of the broader industry, many companies are increasingly focusing on sustainability and setting ambitious targets to reduce their carbon footprints. However, without specific data or commitments from Nova Biomedical, it is challenging to assess their position in this evolving landscape.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Nova Biomedical Corporation is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
